Histologic deterioration and more flares: the case against azathioprine plus methylprednisolone in the treatment of proliferative lupus nephritis.
Chan
Tak Mao
TM
D000893:Anti-Inflammatory Agents / Q000009:adverse effects* / Q000494:pharmacology; D001379:Azathioprine / Q000009:adverse effects* / Q000494:pharmacology; D001706:Biopsy; D003404:Creatinine / Q000097:blood; D003520:Cyclophosphamide / Q000009:adverse effects / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D004359:Drug Therapy, Combination; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects* / Q000494:pharmacology; D007668:Kidney / Q000187:drug effects / Q000473:pathology*; D008181:Lupus Nephritis / Q000188:drug therapy* / Q000473:pathology; D008775:Methylprednisolone / Q000009:adverse effects* / Q000494:pharmacology; D011241:Prednisone / Q000009:adverse effects / Q000494:pharmacology; D016896:Treatment Outcome
D000893:Anti-Inflammatory Agents; D007166:Immunosuppressive Agents; D003520:Cyclophosphamide; D003404:Creatinine; D001379:Azathioprine; D011241:Prednisone; D008775:Methylprednisolone